exRNAdisease

Entry Detail

---



General Information

Database ID: exR0080651 RNA Name: RPS20 RNA Type: mRNA Chromosome: chr8 Starnd: - Coordinate: Start Site(bp): 56067295 End Site(bp): 56074581 External Links: ENSG00000008988

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABT1 chr6 26596953 26600739 + AC005258.1 chr19 2269525 2341172 + AC006064.6 chr12 6556886 6607367 - AC008750.8 chr19 51350373 51368099 - AC091167.2 chr15 90249556 90272208 + AC093827.5 chr4 86886472 86936178 - AC120057.2 chr17 7240427 7244635 - AC135050.2 chr16 31083439 31094956 - ACOT1 chr14 73537143 73543796 + ACTB chr7 5527148 5563784 - ACTG1 chr17 81509971 81523847 - ACTR10 chr14 58200080 58235636 + ACTR1B chr2 97655939 97664044 - ADAP1 chr7 897900 955407 - ADNP2 chr18 80109262 80147523 + ADSL chr22 40346500 40390463 + AGA chr4 177430774 177442437 - AGO3 chr1 35930718 36072500 + AL022238.4 chr22 40346529 40410054 + AL096711.2 chr6 127438406 127519001 - AL132780.3 chr14 22946270 22982258 - AL358113.1 chr9 69035747 69255187 + ALDH4A1 chr1 18871430 18902724 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC064802.1 chr8 114282067 114295839 + AC092117.1 chr16 2777319 2780568 + AC132217.1 chr11 2129121 2129964 - AC140125.2 chr5 177782197 177794396 + AC144652.1 chr7 155295918 155297541 - AC245297.2 chr1 149264252 149264816 + AL031282.2 chr1 1702736 1737688 - Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA